AlveoliX AG
In-vitro lung model for drug testing
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
11.09.2025
Das Finalisten-Feld des Swiss Technology Award 2025 (startupticker.ch)
23.05.2025
Promising Swiss innovations unveiled at VivaTech 2025 (startupticker.ch)
31.10.2024
AlveoliX and AMYRA report breakthroughs (startupticker.ch)
03.10.2024
EU funds AI-driven medical projects powered by Swiss startups (startupticker.ch)
06.06.2024
European consortiums with Swiss startups awarded grants (startupticker.ch)
No Jobs
Videos
Swiss Medtech Award Lung on Chip
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Swiss Innovation Forum
Das Swiss Innovation Forum ist eine nationale Plattform zur gezielten Förderung von Kreativität, Design und Innovation. Das Swiss Innovation Forum bündelt das Wissen von führenden Institutionen im Bereich F&E und Innovation.
AlveoliX AG
In-vitro lung model for drug testing
Website:
www.alveolix.com
Headquarter:
Bern
Foundation Date:
July 2015
Technology:
- Biotech
Sectors:
- Biotech
- Drug development platforms
- Screening
Support received
